Patients’ Physical Response to Thiopental and Alternative Anesthetic Agents in the Setting of Electroconvulsive Therapy
| Autor: | Ashley N Walus, Donna M M Woloschuk, Kayleigh Gordon |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Economic shortage Pharmacy Anesthetic Agent behavioral disciplines and activities Clinical Practice / Pratique Clinique Electroconvulsive therapy Anesthesia mental disorders Anesthetic medicine Pharmacology (medical) Intensive care medicine business medicine.drug |
| Zdroj: | The Canadian Journal of Hospital Pharmacy. 67 |
| ISSN: | 1920-2903 0008-4123 |
| Popis: | Drug shortages continue to be at the forefront of health care concerns.1,2Thiopental, an agent used for anesthesia during electroconvulsive therapy (ECT), became unavailable in North America in August 2010. The sole producer of this drug, Hospira (headquartered in Lake Forest, Illinois), ceased production because of liability concerns if thiopental were used via lethal injection to enforce the death penalty.3 The thiopental shortage altered the practice of ECT, forcing a shift to alternative anesthetics. Of concern were the potentially negative consequences of using alternative agents, such as decreased efficacy and increased incidence of adverse effects.2 This study examined ECT session outcomes, relative to recommended criteria for ECT (as described in Appendix 1), to compare patients’ experiences during ECT performed with thiopental (the main anesthetic agent used in 2009) and their experiences during ECT performed with prescriber-selected alternatives used in 2011, when thiopental was in shortage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|